Immuneering (NASDAQ:IMRX) Given Buy Rating at Needham & Company LLC

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a report released on Monday,Benzinga reports. They presently have a $15.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. Morgan Stanley cut shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Chardan Capital reaffirmed a “buy” rating and issued a $13.00 target price on shares of Immuneering in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Immuneering currently has an average rating of “Hold” and an average target price of $12.80.

Immuneering Trading Down 3.9 %

Shares of IMRX stock traded down $0.08 during mid-day trading on Monday, reaching $1.99. The stock had a trading volume of 462,131 shares, compared to its average volume of 12,745,939. Immuneering has a 1-year low of $1.00 and a 1-year high of $7.68. The firm has a market cap of $61.79 million, a price-to-earnings ratio of -1.01 and a beta of -0.34. The business’s fifty day moving average is $2.05 and its 200-day moving average is $1.78.

Institutional Trading of Immuneering

Several hedge funds have recently added to or reduced their stakes in IMRX. HighTower Advisors LLC grew its holdings in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock worth $132,000 after acquiring an additional 9,400 shares in the last quarter. Corsair Capital Management L.P. purchased a new stake in shares of Immuneering during the 3rd quarter worth $25,000. Tidemark LLC purchased a new position in Immuneering in the third quarter valued at $129,000. Vontobel Holding Ltd. acquired a new stake in Immuneering in the third quarter valued at $25,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Immuneering during the 2nd quarter worth about $44,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.